Global Blood Therapeutics Inc (NASDAQ:GBT) major shareholder Perceptive Advisors Llc acquired 175,000 shares of the company’s stock in a transaction dated Tuesday, December 19th. The stock was acquired at an average price of $38.00 per share, for a total transaction of $6,650,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Global Blood Therapeutics Inc (NASDAQ GBT) traded up $0.15 during mid-day trading on Friday, hitting $56.60. The stock had a trading volume of 968,595 shares, compared to its average volume of 1,824,567. The company has a market cap of $2,600.00 and a price-to-earnings ratio of -22.20. Global Blood Therapeutics Inc has a 52 week low of $14.70 and a 52 week high of $57.75.
Global Blood Therapeutics (NASDAQ:GBT) last announced its earnings results on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.04). During the same period last year, the business earned ($0.58) earnings per share. equities analysts expect that Global Blood Therapeutics Inc will post -2.54 earnings per share for the current year.
A number of large investors have recently bought and sold shares of GBT. State Street Corp lifted its holdings in Global Blood Therapeutics by 217.9% during the 2nd quarter. State Street Corp now owns 2,138,323 shares of the company’s stock worth $58,479,000 after buying an additional 1,465,595 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in Global Blood Therapeutics by 189.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,022,700 shares of the company’s stock worth $62,805,000 after buying an additional 1,323,934 shares in the last quarter. Janus Henderson Group PLC acquired a new position in Global Blood Therapeutics during the 2nd quarter worth $26,919,000. BlackRock Inc. lifted its holdings in Global Blood Therapeutics by 30.0% during the 2nd quarter. BlackRock Inc. now owns 3,404,538 shares of the company’s stock worth $93,114,000 after buying an additional 785,691 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Global Blood Therapeutics by 15.7% during the 2nd quarter. Vanguard Group Inc. now owns 2,933,251 shares of the company’s stock worth $80,224,000 after buying an additional 397,271 shares in the last quarter. 85.72% of the stock is currently owned by hedge funds and other institutional investors.
GBT has been the topic of several research reports. Wedbush restated an “outperform” rating and set a $73.00 price target on shares of Global Blood Therapeutics in a research note on Monday, December 4th. BidaskClub upgraded Global Blood Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 12th. HC Wainwright set a $73.00 price objective on Global Blood Therapeutics and gave the company a “buy” rating in a research note on Monday, December 11th. Oppenheimer set a $53.00 price objective on Global Blood Therapeutics and gave the company a “buy” rating in a research note on Monday, November 13th. Finally, Nomura upped their price objective on Global Blood Therapeutics to $91.00 and gave the company a “buy” rating in a research note on Monday, December 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $62.07.
COPYRIGHT VIOLATION WARNING: “Insider Buying: Global Blood Therapeutics Inc (GBT) Major Shareholder Acquires 175,000 Shares of Stock” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://ledgergazette.com/2018/01/13/perceptive-advisors-llc-buys-175000-shares-of-global-blood-therapeutics-inc-gbt-stock.html.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.